Table 5.
Patient demographics in Anhui Province, Wuhan city, Zhejiang Province, and the whole country.
| Item | Number of people (percentage) | |||
| Anhui(n = 74) | Wuhan(n = 41) | Zhejiang(n = 62) | Whole country(1099) | |
| Age, median, y | 47 (35–56) | 49 (41–58) | 41 (32–52) | 47 (35–58) |
| Sex, male (%) | 48 (64.86) | 30 (73.17) | 36 (58.06) | 637 (57.96) |
| Contact history | 53 (72) | – | 23 (37) | – |
| People from Wuhan or confirmed COVID-19 patient (s) | 53 (71.62) | – | 23 (37.10) | 676/1099 (61.51) |
| Wuhan seafood market or wildlife | 0 (0.00) | 27 (65.85) | 0 (0.00) | 687 (62.51) |
| No | 21 (28.38) | – | 39 (62.90) | 285 (25.93) |
| Familial clustering | 21 (28.38) | – | 21 (33.87) | – |
| Incubation period, median, d | 6 (4–10) | 8 (5–13) | 4 (3–5) | 4 (2–7) |
| Fever | 62 (83.78) | 40 (97.56) | 48 (77.42) | 975 (88.72) |
| Cough | 55 (74.32) | 31 (75.61) | 50 (80.65) | 745 (67.79) |
| Fatigue | 31 (41.89) | 18 (43.90) | 32 (51.61) | 419 (38.1320) |
| Expectoration | 20 (27.03) | 11 (26.83) | 35 (56.45) | 370 (33.67) |
| Difficulty breathing | 5 (6.76) | 22 (53.66) | 2 (3.23) | 205 (18.65) |
| Headache | 16 (21.62) | 3 (7.32) | 21 (33.87) | 150 (13.65) |
| Diarrhea | 5 (6.76) | 1 (2.44) | 3 (4.84) | 42 (3.82) |
| Hemoptysis | 1 (1.35) | 2 (4.88) | 2 (3.23) | 10 (0.91) |
| Symptom onset to admission, median, d | 6 (4–10) | 5 (1–8) | 2 (1–4) | 4 (2–7) |
| Any comorbidities | 34 (45.95) | 13 (31.71) | 20 (32.26) | 261 (23.75) |
| White blood cell count, median, × 109/L | 5.5 (4.4–6.6) | 6.2 (4.1–10.5) | 4.7 (3.5–5.9) | 4.7 (3.5–6.0) |
| Lymphocyte count, × 109/L | 1.0 (0.6–1.5) | 0.8 (0.6–1.1) | 1.0 (0.8–1.5) | 1.0 (0.7–1.3) |
| ESR, median, mm/h | 15 (10–18) | – | – | – |
| CRP, median, mg/L | 17.4 (4.2–49.3) | – | – | ≥10,481/793 |
| Procalcitonin, median, ng/mL | 0.3 (0.1–0.7) | 0.1 (0.1–0.1) | 0.04 (0.03–0.06) | ≥0.5, 35/633 |
| Creatine kinase, median, U/L | 91.4 (53.2–150.1) | 132 (62–139) | 65 (49–101) | ≥200, 90/657 |
| Lactate dehydrogenase, U/L | 269 (191–323) | 286 (242–408) | 205 (184–260) | ≥250, 277/675 |
| Alanine aminotransferase, median, U/L | 23.5 (16–36.5) | 32 (21–50) | 22 (14–34) | ≥40, 158/741 |
| Aspartate aminotransferase, median, U/L | 28.5 (21–38) | 34 (26–48) | 26 (20–32) | ≥40, 168/757 |
| Creatinine, μmol/L | 68 (59.5–80) | 139 (137–140) | 72 (61–84) | ≥133, 12/752 |
| D-dimer, median, mg/L | 0.3 (0.1–0.6) | 0.5 (0.3–1.3) | 0.2 (0.2–0.5) | ≥0.5, 260/560 |
| Pneumonia | 68 (91.89) | – | 61 (98.39) | 972 (88.44) |
| Bilateral involvement | 52 (70.27) | 40 (97.56) | 52 (83.87) | – |
| ICU treatment | 18 (24.32) | – | 1 (1.61) | 55 (5.00) |
| Antiviral | 72 (97.30) | 38 (92.68) | 55 (89) | 393 (36) |
| Antibiotic | 60 (81.08) | 41 (100.00) | 28 (45.16) | 638 (58.05) |
| Steroid | 4 (5.41) | 9 (21.95) | 16 (25.81) | 204 (18.56) |
| Gamma globulin | 15 (20.27) | – | – | 144 (13.10) |
| Interferon | 16 (21.62) | – | 28 (45.16) | – |
| Oxygen therapy | 53 (71.62) | 41 (100.00) | – | 454 (41.31) |
| Noninvasive ventilation | 53 (71.62) | 10 (24.39) | – | 56 (5.10) |
| Invasive ventilation | 0 (0.00) | 2 (4.88) | – | 25 (2.27) |
| ECO | 0 (0.00) | 2 (4.88) | – | 5 (0.45) |
| Length of hospital stay | 13 (10–16) | – | – | 12 (10–14) |
| Death | 1 (1.35) | 6 (14.63) | 0 (0.00) | 15 (1.36) |
| Discharged | 73 (98.65) | 28 (68.29) | 1 (1.61) | 55 (5.00) |